乌帕替尼减轻活动性银屑病关节炎或强直性脊柱炎患者疼痛的效果:三项随机临床试验的事后分析
该事后分析基于三项随机试验(SELECT-PsA 1和2纳入银屑病关节炎,SELECT-AXIS 1纳入强直性脊柱炎),评估乌帕替尼15 mg每日一次对疼痛结局的影响。乌帕替尼较安慰剂自第2周起即有更高比例患者达到疼痛缓解≥30%、≥50%和≥70%,且改善持续至第1年。
要点
- 乌帕替尼15 mg每日一次自第2周起疼痛缓解比例高于安慰剂,改善持续至第1年。
- 银屑病关节炎研究第1年疼痛缓解≥30%/≥50%/≥70%比例分别为64%/48%、58%/42%、38%/22%。
- 强直性脊柱炎研究第1年上述比例分别为76%、72%、54%。
核心结论
- 在活动性银屑病关节炎或强直性脊柱炎患者中,乌帕替尼治疗1年内多个疼痛终点均显示快速且持续的改善。
研究设计与样本
- 三项随机临床试验的事后分析:SELECT-PsA 1和2纳入银屑病关节炎患者,SELECT-AXIS 1纳入强直性脊柱炎患者。
- 患者随机接受乌帕替尼15 mg每日一次或安慰剂(三项研究均包括),或阿达木单抗40 mg隔周一次(仅SELECT-PsA 1)。
主要发现
- 接受乌帕替尼的患者较安慰剂自第2周起即有更高比例达到疼痛缓解≥30%、≥50%和≥70%,改善持续或增加至第1年。
- 银屑病关节炎研究第1年疼痛缓解≥30%/≥50%/≥70%比例:乌帕替尼组分别为64%/48%、58%/42%、38%/22%。
- 强直性脊柱炎研究第1年上述比例:乌帕替尼组分别为76%、72%、54%。
- 银屑病关节炎研究1中阿达木单抗组上述比例分别为59%、49%、32%。
- 从安慰剂转换为乌帕替尼15 mg的患者至第1年可达到与持续乌帕替尼组相似的改善水平(银屑病关节炎研究:46%-60%、35%-49%、15%-34%;强直性脊柱炎研究:83%、72%、46%)。
关键数值与推荐
- 疼痛结局包括患者疼痛总体评估较基线降低≥30%、≥50%和≥70%的患者比例及其他终点。
- 银屑病关节炎研究纳入对既往非生物或生物改善病情抗风湿药应答不足的患者;强直性脊柱炎研究纳入对非甾体抗炎药应答不足且未使用过生物制剂的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA; SELECT-AXIS 1 for AS). METHODS: Patients were randomised to upadacitinib 15 mg once daily or placebo (all 3 studies), or adalimumab 40 mg every other week (SELECT-PsA 1 only). Pain outcomes included proportion of patients achieving ≥30%, ≥50% and ≥70% reduction from baseline in patient global assessment of pain and other end points. RESULTS: A higher proportion of patients receiving upadacitinib versus placebo achieved ≥30%, ≥50% and ≥70% reduction in pain end points as early as week 2; these improvements with upadacitinib were generally sustained or increased through year 1 (PsA 1/2 studies: 64%/48%, 58%/42% and 38%/22%, respectively; SELECT-AXIS 1 study: 76%, 72% and 54%). Results were similar with adalimumab in PsA 1 (59%, 49% and 32%). Patients who switched from placebo to upadacitinib 15 mg were able to reach a similar level of improvement as the continuous upadacitinib groups by year 1 (PsA 1/2 studies: 46%-60%, 35%-49% and 15%-34%; AS study: 83%, 72% and 46%). Results were similar with other pain end points. CONCLUSION: Rapid and sustained improvements in pain outcomes across several end points were consistently shown with upadacitinib over 1 year in patients with active PsA or AS who had either inadequate response to prior non-biologic or biologic disease-modifying antirheumatic drugs (PsA studies) or were biologic-naïve with inadequate response to non-steroidal anti-inflammatory drugs (AS study).
引用
- McInnes IB, Ostor AJK, Mease PJ, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022. PMID: 35332058. doi:10.1136/rmdopen-2021-002049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。